PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.
UNASSIGNED: Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.
UNASSIGNED: Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (p < 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.
UNASSIGNED: Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns.
UNASSIGNED: Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.
UNASSIGNED: Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (p < 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.
UNASSIGNED: Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns.
摘要：
■探讨结膜下注射贝伐单抗抑制化学烧伤后患者角膜新生血管（CorNV）的作用和时机。
■涉及化学烧伤继发的CorNV患者。两次结膜下注射贝伐单抗（每个涉及的象限2.5mg/0.1mL），间隔4周，并跟进了一年。新生血管（NA）占据的区域，累积新生血管长度（NL），平均新生血管直径（ND），评价最佳矫正视力(BCVA)和眼内压(IOP).并发症也被记录。
■涉及11例CorNV患者。八名患者有手术史（四名有羊膜移植，一个人做了角膜移植术,三人进行了羊膜移植和角膜移植术）。NA减少，NL,和ND在每个时间点与基线相比具有统计学意义(p<0.01)。在1个月内发展的CorNV有很大的回归，发现具有纤维血管膜的血管比预处理更狭窄和更短。五名患者的BCVA有所改善（从一到五行），五名患者保持不变，与治疗前相比，一名患者下降。
■结膜下贝伐单抗注射液对CorNV的消退具有特殊的潜力，尤其是化学烧伤后1个月内新形成的患者。
■涉及化学烧伤继发的CorNV患者。两次结膜下注射贝伐单抗（每个涉及的象限2.5mg/0.1mL），间隔4周，并跟进了一年。新生血管（NA）占据的区域，累积新生血管长度（NL），平均新生血管直径（ND），评价最佳矫正视力(BCVA)和眼内压(IOP).并发症也被记录。
■涉及11例CorNV患者。八名患者有手术史（四名有羊膜移植，一个人做了角膜移植术,三人进行了羊膜移植和角膜移植术）。NA减少，NL,和ND在每个时间点与基线相比具有统计学意义(p<0.01)。在1个月内发展的CorNV有很大的回归，发现具有纤维血管膜的血管比预处理更狭窄和更短。五名患者的BCVA有所改善（从一到五行），五名患者保持不变，与治疗前相比，一名患者下降。
■结膜下贝伐单抗注射液对CorNV的消退具有特殊的潜力，尤其是化学烧伤后1个月内新形成的患者。
